Next-generation ALK inhibitors excel after crizotinib failure
ALK fusion-gene–positive lung cancer occurs in approximately 5 % of patients with advanced NSCLC . The ALK inhibitor crizotinib demonstrates significant initial efficacy in patients with ALK-positive advanced NSCLC. However, most patients eventually develop resistance, with the central nervous system (CNS) being one of the most common sites of first progression. Approximately half of these patients develop CNS metastases during crizotinib treatment. Next-generation ALK inhibitors represent efficacious options for patients who have progressed on crizotinib.